Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin [Yahoo! Finance]
Lexicon Pharmaceuticals, Inc. (LXRX)
Last lexicon pharmaceuticals, inc. earnings: 4/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
lexpharma.com/investors
Company Research
Source: Yahoo! Finance
Data from the new post hoc analysis showed that treatment with sotagliflozin improved glycemic control in the given patient population, while also successfully lowering A1C (blood sugar levels), body weight and systolic blood pressure. Per the press release, in a subgroup of patients with type 1 diabetes and CKD, treatment with sotagliflozin led to similar reductions in A1C, body weight and systolic blood pressure in the CKD and total cohorts, relative to placebo. Treatment with sotagliflozin was also associated with the same risks of severe hypoglycemia between the two cohorts. This might have hurt investors' sentiments and resulted in the stock to go down 10.3% on Mar 12, following the announcement of the news. The company is currently preparing to resubmit the new drug application seeking approval for sotagliflozin as an adjunct to insulin therapy in people with type 1 diabetes and CKD. Shares of Lexicon have rallied 9.1% in the past year against the industry's decline of
Show less
Read more
Impact Snapshot
Event Time:
LXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXRX alerts
High impacting Lexicon Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
LXRX
News
- Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- Lexicon Pharmaceuticals to Host 2024 Investor Day [Yahoo! Finance]Yahoo! Finance
- Lexicon Pharmaceuticals to Host 2024 Investor DayGlobeNewswire
- All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy [Yahoo! Finance]Yahoo! Finance
- Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
LXRX
Earnings
- 3/11/24 - Beat
LXRX
Sec Filings
- 3/26/24 - Form ARS
- 3/26/24 - Form DEFA14A
- 3/26/24 - Form DEF
- LXRX's page on the SEC website